Refine
Has Fulltext
- yes (62)
Is part of the Bibliography
- yes (62)
Year of publication
Document Type
- Journal article (57)
- Report (2)
- Review (2)
- Book article / Book chapter (1)
Language
- English (62)
Keywords
- amyotrophic lateral sclerosis (4)
- Neurotrophic factors (3)
- ciliary neurotrophic factor (3)
- spinal muscular atrophy (3)
- BDNF (2)
- CNTF (2)
- RNA (2)
- Schwann cells (2)
- TrkB (2)
- autophagy (2)
- motoneurons (2)
- neuromuscular junction (2)
- neurons (2)
- spinal cord (2)
- synaptic plasticity (2)
- 3D cell culture (1)
- Aging (1)
- Alzheimer's disease (1)
- Alzheimers disease (1)
- Alzheimer’s disease (1)
- Amyotrophic-lateral-sclerosis (1)
- Associative learning (1)
- Astrocytes ; Schwann cells ; Interferon-gamma ; Fibroblast growth factor ; Cyclic AMP (1)
- Axon degeneration (1)
- Axon growth (1)
- Axonal degeneration (1)
- Axonal transport (1)
- BDNF stimulation (1)
- BSTA (1)
- Brain (1)
- C. elegans (1)
- C9orf72 (1)
- Cells (1)
- DAPI staining (1)
- DNA repeat expansion (1)
- DRD1 (1)
- Diabetic polyneuropathy (1)
- Drosophilia (1)
- Exercise (1)
- FGF-5 (1)
- Facial Nerve Transection (1)
- Fear conditioning (1)
- Fibroblast Growth Factor (1)
- GPCR (1)
- Glutamatergic synapses (1)
- Hippocampus (1)
- IGF-I (1)
- Immunopanning (1)
- Insulinlike Growth Factor (1)
- Intermediate filaments (1)
- Lacking neurofilaments (1)
- MAP1B (1)
- Microtubules (1)
- Missense mutation (1)
- Molecular neuroscience (1)
- Motoneuron disease (1)
- Motor behaviour (1)
- Motor nerve biopsy (1)
- Motor neuron disease; Ciliary neurotrophic factor; Brain-derived neurotrophic factor; Animal models; Neurotrophic factors (1)
- Mouse model (1)
- Mus spretus (1)
- NGF gene family (1)
- NMJ–neuromuscular junction (1)
- Nervenzelle (1)
- Neurobiologie (1)
- Neurofilament (1)
- Neuropathy (1)
- Neurotrophin (1)
- Object recognition (1)
- PKB/Akt phosphorylation (1)
- PLEKHG5 (1)
- Phosphorylation (1)
- Plasma-membrane (1)
- Pleckstrin homology containing family member 5 (Plekhg5) (1)
- Progressive motor neuronopathy (1)
- Protein kinase B (1)
- RNA splicing (1)
- RNA transport (1)
- RNA-binding proteins (1)
- Rictor-mTOR complex (1)
- SAP47 gene (1)
- SMN (1)
- SMN granules (1)
- Spinal Muscular-arthropy (1)
- Stat3 (1)
- Stathmin (1)
- Syap1 knockout (1)
- Syap1 localization (1)
- Tdp-43 (1)
- Transcription (1)
- Transgenic mice (1)
- Vascular plasticity (1)
- Viability (1)
- YB-1 (1)
- actin messenger RNA (1)
- adenocarcinoma of the lung (1)
- apoptosis (1)
- axonal degeneration (1)
- axonal transcriptome (1)
- axons (1)
- basal ganglia (1)
- cerebral amyloid angiopathy (1)
- cerebral blood flow (1)
- cerebral small vessel disease (1)
- chick (1)
- ciliary neuron (1)
- ciliary neurotrophic factor (CNTF) (1)
- ciliary-neurotrophic factor (1)
- comet assay (1)
- cortico-striatal synapse (1)
- cross-sectional studies (1)
- cytosol (1)
- dSPN (1)
- degeneration (1)
- demyelination (1)
- determining gene-product (1)
- direct pathway (1)
- dynamics of ribosomal assembly (1)
- early-onset predictors (1)
- electron tomography (1)
- enrichment (1)
- exercise (1)
- factor prevents (1)
- frontotemporal dementia (1)
- fused in sarcoma (1)
- gene targeting (1)
- genome wide (1)
- genome-wide association studies (1)
- hippocampus (1)
- homologous recombination (1)
- hypertensive arteriopathy (1)
- iPSC (induced pluripotent stem cells) (1)
- immune response (1)
- immunoprecipitation (1)
- injury (1)
- insulin (1)
- insulin-likegrowth factor I (1)
- interacts (1)
- interleukin 6 (1)
- interspeific backcross (1)
- intravital imaging (1)
- lIF (1)
- linkage (1)
- lung and intrathoracic tumors (1)
- medicine (1)
- memory (1)
- metastasis (1)
- mild cognitive impairment (1)
- molecular neuroscience (1)
- motoneuron (1)
- motoneuron (MN) (1)
- motoneuron disease (1)
- motor axons (1)
- motor learning (1)
- motor neuron degeneration (1)
- mulitple-sclerosis patients (1)
- myelin (1)
- nerve lesion (1)
- neurofilaments (1)
- neuron migration (1)
- neurotrophic factor (1)
- neurotrophic molecules (1)
- neurotrophins (1)
- nicotinamide (1)
- non-small cell lung cancer (1)
- nonneuronaI cells (1)
- nuclear ribonucleoprotein-R (1)
- presynaptic ER dynamics (1)
- programmed cell death (1)
- protein interactions (1)
- rat (1)
- receptor (1)
- recombinant proteins (1)
- regulation (1)
- restriction fragment length polymorphism (1)
- secondary lung tumors (1)
- skeletal muscle (1)
- spontaneously hypertensive stroke-prone rat (1)
- subcellular trafficking (1)
- survival (1)
- synaptic vesicles (1)
- thoracic diaphragm (1)
- transactivation (1)
- transcription-3 (STAT3) (1)
- uper-resolution array tomography (1)
- vector cloning (1)
- β-actin mRNA (1)
Institute
- Institut für Klinische Neurobiologie (59)
- Theodor-Boveri-Institut für Biowissenschaften (5)
- Neurologische Klinik und Poliklinik (4)
- Institut für Anatomie und Zellbiologie (3)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (2)
- Frauenklinik und Poliklinik (1)
- Institut für Psychologie (1)
- Lehrstuhl für Biochemie (1)
- Medizinische Klinik und Poliklinik II (1)
Background
We aimed to accurately estimate the frequency of a hexanucleotide repeat expansion in C9orf72 that has been associated with a large proportion of cases of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
Methods
We screened 4448 patients diagnosed with ALS (El Escorial criteria) and 1425 patients with FTD (Lund-Manchester criteria) from 17 regions worldwide for the GGGGCC hexanucleotide expansion using a repeat-primed PCR assay. We assessed familial disease status on the basis of self-reported family history of similar neurodegenerative diseases at the time of sample collection. We compared haplotype data for 262 patients carrying the expansion with the known Finnish founder risk haplotype across the chromosomal locus. We calculated age-related penetrance using the Kaplan-Meier method with data for 603 individuals with the expansion.
Findings
In patients with sporadic ALS, we identified the repeat expansion in 236 (7·0%) of 3377 white individuals from the USA, Europe, and Australia, two (4·1%) of 49 black individuals from the USA, and six (8·3%) of 72 Hispanic individuals from the USA. The mutation was present in 217 (39·3%) of 552 white individuals with familial ALS from Europe and the USA. 59 (6·0%) of 981 white Europeans with sporadic FTD had the mutation, as did 99 (24·8%) of 400 white Europeans with familial FTD. Data for other ethnic groups were sparse, but we identified one Asian patient with familial ALS (from 20 assessed) and two with familial FTD (from three assessed) who carried the mutation. The mutation was not carried by the three Native Americans or 360 patients from Asia or the Pacific Islands with sporadic ALS who were tested, or by 41 Asian patients with sporadic FTD. All patients with the repeat expansion had (partly or fully) the founder haplotype, suggesting a one-off expansion occurring about 1500 years ago. The pathogenic expansion was non-penetrant in individuals younger than 35 years, 50% penetrant by 58 years, and almost fully penetrant by 80 years.
Interpretation
A common Mendelian genetic lesion in C9orf72 is implicated in many cases of sporadic and familial ALS and FTD. Testing for this pathogenic expansion should be considered in the management and genetic counselling of patients with these fatal neurodegenerative diseases.
Local axonal function of STAT3 rescues axon degeneration in the pmn model of motoneuron disease
(2012)
Axonal maintenance, plasticity, and regeneration are influenced by signals from neighboring cells, in particular Schwann cells of the peripheral nervous system. Schwann cells produce neurotrophic factors, but the mechanisms by which ciliary neurotrophic factor (CNTF) and other neurotrophic molecules modify the axonal cytoskeleton are not well understood. In this paper, we show that activated signal transducer and activator of transcription-3 (STAT3), an intracellular mediator of the effects of CNTF and other neurotrophic cytokines, acts locally in axons of motoneurons to modify the tubulin cytoskeleton. Specifically, we show that activated STAT3 interacted with stathmin and inhibited its microtubule-destabilizing activity. Thus, ectopic CNTF-mediated activation of STAT3 restored axon elongation and maintenance in motoneurons from progressive motor neuronopathy mutant mice, a mouse model of motoneuron disease. This mechanism could also be relevant for other neurodegenerative diseases and provide a target for new therapies for axonal degeneration.
Synapse-associated protein 1 (Syap1/BSTA) is the mammalian homologue of Sap47 (synapse-associated protein of 47 kDa) in Drosophila. Sap47 null mutant larvae show reduced short-term synaptic plasticity and a defect in associative behavioral plasticity. In cultured adipocytes, Syap1 functions as part of a complex that phosphorylates protein kinase B alpha/Akt1 (Akt1) at Ser\(^{473}\) and promotes differentiation. The role of Syap1 in the vertebrate nervous system is unknown. Here, we generated a Syap1 knock-out mouse and show that lack of Syap1 is compatible with viability and fertility. Adult knock-out mice show no overt defects in brain morphology. In wild-type brain, Syap1 is found widely distributed in synaptic neuropil, notably in regions rich in glutamatergic synapses, but also in perinuclear structures associated with the Golgi apparatus of specific groups of neuronal cell bodies. In cultured motoneurons, Syap1 is located in axons and growth cones and is enriched in a perinuclear region partially overlapping with Golgi markers. We studied in detail the influence of Syap1 knockdown and knockout on structure and development of these cells. Importantly, Syap1 knockout does not affect motoneuron survival or axon growth. Unexpectedly, neither knockdown nor knockout of Syap1 in cultured motoneurons is associated with reduced Ser\(^{473}\) or Thr\(^{308}\) phosphorylation of Akt. Our findings demonstrate a widespread expression of Syap1 in the mouse central nervous system with regionally specific distribution patterns as illustrated in particular for olfactory bulb, hippocampus, and cerebellum.
Spinal motoneurons innervating skeletal muscle were amongst the first neurons shown to require the presence of their target cells to develop appropriately. Isolated embryonie chick and rat motoneurons have been used to identify neurotrophic factors and cytokines capable of supporting the survival of developing motoneurons. Such factors include ciliary neurotrophic factor (CNTF), which is present physiologically in high amounts in myelinating Schwann cells of peripheral nerves, and brain-derived neurotrophic factor (BDNF) which is synthesized in skeletal muscle and, after peripheral nerve lesion. in Schwann cells. These factors have been further analyzed for their physiological significance in maintaining motoneuron function in vivo, and for their potential therapeutic usefulness in degenerative motoneuron disease. Both CNTF and BDNF are capable of rescuing injured facial motoneurons in newbom rats. Furthermore, CNTF prolongs survival and improves motor function of pmn mice, an animal model for degenerative motoneuron disease, by preventing degeneration of motoneuron axons and somata. Thus treatment of human motoneuron disease with neurotrophic factors should be possible, provided that rational means for application of these factors can be established considering also the appearance of potential side effects.
Most RNAs within polarized cells such as neurons are sorted subcellularly in a coordinated manner. Despite advances in the development of methods for profiling polyadenylated RNAs from small amounts of input RNA, techniques for profiling coding and non-coding RNAs simultaneously are not well established. Here, we optimized a transcriptome profiling method based on double-random priming and applied it to serially diluted total RNA down to 10 pg. Read counts of expressed genes were robustly correlated between replicates, indicating that the method is both reproducible and scalable. Our transcriptome profiling method detected both coding and long non-coding RNAs sized >300 bases. Compared to total RNAseq using a conventional approach our protocol detected 70% more genes due to reduced capture of ribosomal RNAs. We used our method to analyze the RNA composition of compartmentalized motoneurons. The somatodendritic compartment was enriched for transcripts with post-synaptic functions as well as for certain nuclear non-coding RNAs such as 7SK. In axons, transcripts related to translation were enriched including the cytoplasmic non-coding RNA 7SL. Our profiling method can be applied to a wide range of investigations including perturbations of subcellular transcriptomes in neurodegenerative diseases and investigations of microdissected tissue samples such as anatomically defined fiber tracts.
The fatal neurodegenerative disorders amyotrophic lateral sclerosis and spinal muscular atrophy are, respectively, the most common motoneuron disease and genetic cause of infant death. Various in vitro model systems have been established to investigate motoneuron disease mechanisms, in particular immortalized cell lines and primary neurons. Using quantitative mass-spectrometry-based proteomics, we compared the proteomes of primary motoneurons to motoneuron-like cell lines NSC-34 and N2a, as well as to non-neuronal control cells, at a depth of 10,000 proteins. We used this resource to evaluate the suitability of murine in vitro model systems for cell biological and biochemical analysis of motoneuron disease mechanisms. Individual protein and pathway analysis indicated substantial differences between motoneuron-like cell lines and primary motoneurons, especially for proteins involved in differentiation, cytoskeleton, and receptor signaling, whereas common metabolic pathways were more similar. The proteins associated with amyotrophic lateral sclerosis also showed distinct differences between cell lines and primary motoneurons, providing a molecular basis for understanding fundamental alterations between cell lines and neurons with respect to neuronal pathways with relevance for disease mechanisms. Our study provides a proteomics resource for motoneuron research and presents a paradigm of how mass-spectrometry-based proteomics can be used to evaluate disease model systems.
TrkB mediates the effects of brain-derived neurotrophic factor (BDNF) in neuronal and nonnneuronal cells. Based on recent reports that TrkB can also be transactivated through epidermal growth-factor receptor (EGFR) signaling and thus regulates migration of early neurons, we investigated the role of TrkB in migration of lung tumor cells. Early metastasis remains a major challenge in the clinical management of non-small cell lung cancer (NSCLC). TrkB receptor signaling is associated with metastasis and poor patient prognosis in NSCLC. Expression of this receptor in A549 cells and in another adenocarcinoma cell line, NCI-H441, promoted enhanced migratory capacity in wound healing assays in the presence of the TrkB ligand BDNF. Furthermore, TrkB expression in A549 cells potentiated the stimulatory effect of EGF in wound healing and in Boyden chamber migration experiments. Consistent with a potential loss of cell polarity upon TrkB expression, cell dispersal and de-clustering was induced in A549 cells independently of exogeneous BDNF. Morphological transformation involved extensive cytoskeletal changes, reduced E-cadherin expression and suppression of E-cadherin expression on the cell surface in TrkB expressing tumor cells. This function depended on MEK and Akt kinase activity but was independent of Src. These data indicate that TrkB expression in lung adenoma cells is an early step in tumor cell dissemination, and thus could represent a target for therapy development.
Motoneuron diseases represent a m&jor challenge to modern neurology, yet their clinical manifestations ware first described more than hundred years ago, and despite many studies the etiology of these diseases ramd,ns obscure with no effective treatments having been reported. Although progress has been made in establishing genetic linkage in the rare inherited for.ms of these diseases such as familial amyotrophic lateral scleriosisl , spinal mDscular atrophy and X-linked bulbo-spinal-mDscular atrophy, this new information has not yet affected therapeutic techniques. During the last few years several important steps have been taken concerning the physiological mechanisms involved in motoneuron survival during development, after lesion and in animal models of degenerative diseases, the molecular clOning of several new neurotrophic factors (brain-derived neurotrophic factor (BDNP), neurotrophin-3 and-4 (NT-3 and NT-4) and ciliary neurotrophic factor (CNTP)); the identification of a gene family of receptor molecules for same of these factors, progress in the understanding of the effects of polypeptide growth factors on muscle cell differentiation, neuronal sprouting (insulin-like growth factor-I and -11 (IGF-I and IGF-II), and in vitro motoneuronal survival (CNTF, IGF-I and -II and basic FGF). These findings have raised new hopes in that they could lead to a better understanding of the pathophysiological processes underlying these diseases, and that the pharmacological use of same of these newly characterized neurotrophic factors could present new possibilities for the treatment of these diseases.
At early developmental stages (embryonic day 7, E7), chick paravertebral sympathetic ganglia contain a cell population that divides in culture while expressing various neuronal properties. In an attempt to identify factors that control neuronal proliferation, we found that ciliary neurotrophic factor (CNTF) specifically inhibits the proliferation of those cells expressing neuronal markers. In addition, CNTF affects the differentiation of sympathetic ganglion cells by inducing the expression of vasoactive intestinal peptide immunoreactivity (VIP-IR). After 1 day in culture, tyrosine hydroxylase immunoreactivity (TH-I R) was expressed by about 86% of the cells whereas VIP-IR was virtually absent. In the presence of CNTF, 50%-60% of the cells expressed VIP-IR after 4 days in culture; however, none of the cells expressed VIP-IR in the absence of CNTF. These results, and the demonstration of cells that express both VIP and TH-IR, indicate that VIP is induced in cells that initially express tyrosine hydroxylase. The findings suggest a potential role for CNTF as a factor affecting the proliferation and differentiation of developing sympathetic neurons.
Leukemia inhibitory factor (LIF) and Ciliary Neurotrophic factor (CNTF) are members of the interleukin-6 family of cytokines, defined by use of the gp130 molecule as an obligate receptor. In the murine experimental autoimmune encephalomyelitis (EAE) model, antagonism of LIF and genetic deletion of CNTF worsen disease. The potential mechanism of action of these cytokines in EAE is complex, as gp130 is expressed by all neural cells, and could involve immuno-modulation, reduction of oligodendrocyte injury, neuronal protection, or a combination of these actions. In this study we aim to investigate whether the beneficial effects of CNTF/LIF signalling in EAE are associated with axonal protection; and whether this requires signalling through oligodendrocytes. We induced MOG\(_{35-55}\) EAE in CNTF, LIF and double knockout mice. On a CNTF null background, LIF knockout was associated with increased EAE severity (EAE grade 2.1\(\pm\)0.14 vs 2.6\(\pm\)0.19; P<0.05). These mice also showed increased axonal damage relative to LIF heterozygous mice, as indicated by decreased optic nerve parallel diffusivity on MRI (1540\(\pm\)207 \(\mu\)m\(^2\)-/s vs 1310\(\pm\)175 \(\mu\)m\(^2\)-/s; P<0.05), and optic nerve (-12.5%) and spinal cord (-16%) axon densities; and increased serum neurofilament-H levels (2.5 fold increase). No differences in inflammatory cell numbers or peripheral auto-immune T-cell priming were evident. Oligodendrocyte-targeted gp130 knockout mice showed that disruption of CNTF/LIF signalling in these cells has no effect on acute EAE severity. These studies demonstrate that endogenous CNTF and LIF act centrally to protect axons from acute inflammatory destruction via an oligodendrocyte-independent mechanism.